299172-48-8

Usage

Uses

Used in Metabolic Studies:
[glucose-(13)C6]-1-O-(β-D-glucopyranosyl)-D-erythro-sphingosine is used as a tracer compound for investigating glucose metabolism. The labeled glucose molecule in [glucose-(13)C6]-1-O-(β-D-glucopyranosyl)-D-erythro-sphingosine enables researchers to track and analyze metabolic pathways, providing insights into the processes of glucose metabolism and sphingolipid biosynthesis.
Used in Lipid Research:
In the field of lipid research, [glucose-(13)C6]-1-O-(β-D-glucopyranosyl)-D-erythro-sphingosine is utilized as a model compound to study the structure, function, and interactions of sphingolipids within biological systems. [glucose-(13)C6]-1-O-(β-D-glucopyranosyl)-D-erythro-sphingosine's unique structure and isotopic labeling make it a valuable asset for understanding the role of sphingolipids and glucose in cellular processes and disease states.
Used in Pharmaceutical Industry:
Within the pharmaceutical industry, [glucose-(13)C6]-1-O-(β-D-glucopyranosyl)-D-erythro-sphingosine may be used as a starting material or intermediate in the synthesis of therapeutic agents targeting metabolic disorders and lipid-related diseases. Its unique properties and isotopic labeling can aid in the development of novel drugs and therapies.
Used in Diagnostic Applications:
[glucose-(13)C6]-1-O-(β-D-glucopyranosyl)-D-erythro-sphingosine can be employed in the development of diagnostic tools and tests for monitoring glucose metabolism and sphingolipid levels in various conditions, potentially aiding in the early detection and management of related diseases.
Used in Nutritional Research:
In nutritional research, [glucose-(13)C6]-1-O-(β-D-glucopyranosyl)-D-erythro-sphingosine can be used to study the absorption, distribution, metabolism, and excretion of glucose and sphingolipids in the human body, contributing to a better understanding of dietary impacts on health and disease.

Upstream product

• 299172-58-0 3-O-benzoyl-N-tert-butoxycarbonyl-1-O-tritylsphingosine 
• 299172-62-6 (+)-tert-butyl {(1S,2R,3E)-2-Hydroxy-1-[(trityloxy)methyl]heptadec-3-en-1-yl}carbamate 
• 263558-18-5 tert-butyl 4-[(1R,2E)-1-benzoyloxyhexadec-2-enyl]-2,2-dimethyloxazolidine-3-carboxylate 
• 299172-54-6 [glucose-U-(13)C]-2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl trichloroacetimidate 
• 4201-60-9 3-O-benzoyl-D-erythro-sphingosine 
• 115464-04-5 tert-butyl (4S)-4-[(1S,2E)-1-hydroxy-2-hexadecenyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 
• 115464-03-4 tert-butyl (4S)-4-[(1R,2E)-1-hydroxy-2-hexadecenyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 
• 116467-63-1 N-tert-butyloxycarbonylsphingosine 
• 115464-01-2 (4S,1'R)-4-(1'-Hydroxy-2'-hexadecinyl)-2,2-dimethyl-3-oxazolidincarbonsaeure-tert-butylester 
• 18459-13-7 (2S,3R,4E)-3-O-benzoyl-N-trifluoroacetyl-4-sphingenine 
• 299172-60-4 [glucose-U-(13)C]-3-O-benzoyl-1-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-N-trifluoroacetyl-D-erythro-sphingosine 

Relevant academic research and scientific papers

Practical syntheses of [13C]- and [14C]-labelled glucosphingolipids

Synthetic routes to [glucose-U-14C]-1-O-(β-D-glucopyranosyl)-N-stearoyl-D-erythro-sp hingosine 1b and to [glucose-13C6]-1-O-(β-D-glucopyranosyl)sphingosine ([glucose-13C6]glucopsychosine, 2b) are described. Whereas the protected ceramide precursor for lb was prepared using conventional methodology, two new strategies were developed in the course of the synthesis of 2b. Of these, one relies on keeping a protecting group in place at all times to avoid the handling difficulties associated with sphingosine 4, while the other generates a protected derivative (24) of sphingosine indirectly by means of a Mitsunobu inversion.